Antibodies to p53 - can they serve as tumor markers in patients with malignantlymphomas?

Barbara Jezeršek Novaković (Author), Srdjan Novaković (Author)

Abstract

Background. Tumor suppressor gene p53 is mutated in approximately 21% of patients with nonHodgkin's lymphomas (the percentage varying from 0 up to 67% depending upon the histological type). Most of the mutations are point missense mutations resulting in nuclear accumulation of altered protein. Roughly one third of patients with overexpression of p53 protein develop circulating anti p53 antibodies. The present study was aimed at defining the usefulness of serial serological determinations of autoantibodies to p53 for clinical follow up of NHL patients. Patients and methods. Serum levels of antibodies to p53 were determined in various time intervals in three lymphoma patients (who had elevated serum levels at the time of diagnosis) for maximum two years using the commercially available ELISA kit p53-Autoantikoerper ELISA2. Generation. Results. In all three cases the temporal patterns of anti p53 antibodies reflected accurately disease progression or regression, and even foretold a relapse ten months in advance. The reflection of disease regression by autoantibodies lagged approximately three months behind the morphological disappearance of the disease due to a long half life of the antibodies. Conclusion. Our results confirmed the usefulness of antibodies to p53 as tumor markers for follow up of lymphoma patients, yet the subset of patients that could be appropriately followed up with this method is very limited due to the low proportion of patients that develop immune response to p53 protein.

Keywords

No keyword data available

Data

Language:	English
Year of publishing:	2000
Typology:	1.01 - Original Scientific Article
Organization:	OI - Institute of Oncology
Publisher:	Slovenian Medical Association - Slovenian Association of Radiology, Nuclear Medicine Society, Slovenian Society far Radiotherapy and Oncology, and Slovenian Cancer Society
UDC:	616-006
COBISS:	11946457
ISSN:	1318-2099
Views:	19
Downloads:	4
Average score:	0 (0 votes)
Metadata:

Other data

Secondary language:	Slovenian
Secondary title:	[Serumska protitelesa proti proteinu p53 kot tumorski označevalci za sledenje bolnikov z Ne-Hodgkinovimi limfomi?]
Secondary abstract:	Izhodišče. Mutacije tumorskega supresorskega gena se pojavljajo pri približno 21% bolnikov z Ne-Hodgkinovimi limfomi (odstotek variira od 0 do 67% glede na histološki tip Ne-Hodgkinovega limfoma). Prevladujejo t.i. mutacije s spremenjenim smislom (mutacije"missense"), ki posledično privedejo do kopičenja spremenjenega proteina v jedrih tumorskih celic. Približno tretjina bolnikov, pri katerih se spremenjeni protein p53 kopiči v jedrih tumorskih celic, se na takšno kopičenje odzove z nastankom krožečih protiteles proti proteinu p53. S pričujočo raziskavo smo želeli določiti dinamiko gibanja serumskih protiteles proti proteinu p53 glede na trenutno stanje bolezni in naosnovi tega sklepati o vrednosti protiteles proti proteinu p53 kot tumorskihoznačevalcev za sledenje bolezni. Bolniki in metode. Serumsko koncentracijo protiteles proti proteinu p53 smo določali v različnih časovnih razmikih (v skupnem trajanju največ dveh let) pri treh bolnikih z Ne-Hodgkinovim limfomom in sicer z ELISA metodo p53-Autoantikoerper ELISA 2. Generation. Rezultati. Pri vseh treh bolnikih je dinamika gibanja serumskih protiteles proti proteinu p53 natančno odražala izboljšanje ali poslabšanje maligne bolezni, naraščanje koncentracije protiteles smo namreč opazili celo že deset mesecev prej, preden smo klinično potrdili ponovitev bolezni. Upadanje koncentracije protiteles proti proteinu p53, kot odraz zmanjševanja tumorske mase, pa je zaostajalo približno dva do tri mesece za klinično sliko,kar je seveda posledica dolgega razpolovnega časa omenjenih protiteles. Zaključek. Naši rezultati potrjujejo, da so serumska protitelesa proti proteinu p53 primerna kot tumorski označevalci za sledenje bolnikov z Ne- Hodgkinovimi limfomi. Žal pa je število bolnikov, pri katerih lahko uporabimo takšen način sledenja, zelo omejeno, ker se le manjši delež bolnikov na kopičenje spremenjenega p53 proteina v jedrih tumorskih celic odzove z nastankom protiteles.
Secondary keywords:	Lymphoma, non-Hodgkin's;Protein p53;Tumor markers, biological;Autoantibodies;Prognosis;
Source comment:	BSDOCID54016;
Pages:	str. 301-306
Volume:	ǂLetn. ǂ34
Issue:	ǂšt. ǂ3
Chronology:	2000
ID:	22609137